fda warning compounding semaglutide september 2025 issued 25 letters to telehealth companies for false and misleading claims about compounded GLP-1 products. Unlike FDA-approved drugs, these products have not been proven to be safe, effective, or of Beyond the Headlines: FDA Warning

What distinguishes Retatrutide from dual agonists like tirzepatide

tissue culture (TC) flasks

Safety profile for regular and compounded tirzepatide Known side effects for both forms Common side effects: nausea, vomiting, diarrhea, constipation, abdominal pain, decreased appetite, injection-site reactions

GLP-1 receptor agonists (including medications like semaglutide, liraglutide, and tripeptide) mimic the action of this natural hormone

For example, semaglutide has a half-life of 1 week and would therefore need to be held for 3 weeks

For people following a semaglutide dosing chart , this means the escalation from 1.7 mg to 2.4 mg is the critical transition point where allodynia risk appears to increase most significantly